Literature DB >> 30309641

Proton Beam Therapy and Carbon Ion Radiotherapy for Hepatocellular Carcinoma.

Smith Apisarnthanarax1, Stephen R Bowen2, Stephanie E Combs3.   

Abstract

Charged particle therapy with proton beam therapy (PBT) and carbon ion radiotherapy (CIRT) has emerged as a promising radiation modality to minimize radiation hepatotoxicity while maintaining high rates of tumor local control. Both PBT and CIRT deposit the majority of their dose at the Bragg peak with little to no exit dose, resulting in superior sparing of normal liver tissue. CIRT has an additional biological advantage of increased relative biological effectiveness, which may allow for increased hypofractionation regimens. Retrospective and prospective studies have demonstrated encouragingly high rates of local control and overall survival and low rates of hepatotoxicity with PBT and CIRT. Ongoing randomized trials will evaluate the value of PBT over photons and other standard liver-directed therapies and future randomized trials are needed to assess the value of CIRT over PBT.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 30309641     DOI: 10.1016/j.semradonc.2018.06.008

Source DB:  PubMed          Journal:  Semin Radiat Oncol        ISSN: 1053-4296            Impact factor:   5.934


  3 in total

1.  Proton Therapy for Primary Renal Cell Carcinoma: The First Nationwide Retrospective Study in Japan.

Authors:  Nobuyoshi Fukumitsu; Hitoshi Ishikawa; Takeshi Arimura; Hitoshi Wada; Tomoaki Okimoto; Yoshitaka Sato; Hiromitsu Iwata; Shosei Shimizu; Hideyuki Sakurai
Journal:  In Vivo       Date:  2020 Sep-Oct       Impact factor: 2.155

2.  A preliminary study of hepatocellular carcinoma post proton beam therapy using MRI as an early prediction of treatment effectiveness.

Authors:  Shen-Yen Lin; Chien-Ming Chen; Bing-Shen Huang; Ying-Chieh Lai; Kuang-Tse Pan; Shi-Ming Lin; Sung-Yu Chu; Jeng-Hwei Tseng
Journal:  PLoS One       Date:  2021-03-23       Impact factor: 3.240

3.  Durvalumab with or without tremelimumab combined with particle therapy for advanced hepatocellular carcinoma with macrovascular invasion: protocol for the DEPARTURE phase Ib trial.

Authors:  Sadahisa Ogasawara; Keisuke Koroki; Hirokazu Makishima; Masaru Wakatsuki; Asahi Takahashi; Sae Yumita; Miyuki Nakagawa; Takamasa Ishino; Keita Ogawa; Kisako Fujiwara; Terunao Iwanaga; Takafumi Sakuma; Naoto Fujita; Ryuta Kojima; Hiroaki Kanzaki; Kazufumi Kobayashi; Soichiro Kiyono; Masato Nakamura; Naoya Kanogawa; Tomoko Saito; Takayuki Kondo; Ryo Nakagawa; Shingo Nakamoto; Ryosuke Muroyama; Tetsuhiro Chiba; Yoshihito Ozawa; Yohei Kawasaki; Tomoya Kurokawa; Hideki Hanaoka; Hiroshi Tsuji; Naoya Kato
Journal:  BMJ Open       Date:  2022-04-08       Impact factor: 2.692

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.